120 related articles for article (PubMed ID: 19818090)
1. Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection.
Loera-Arias MJ; Martínez-Pérez AG; Barrera-Hernández A; Ibarra-Obregón ER; González-Saldívar G; Martínez-Ortega JI; Rosas-Taraco A; Villanueva-Olivo A; Esparza-González SC; Villatoro-Hernandez J; Saucedo-Cárdenas O; Montes-de-Oca-Luna R
J Cell Mol Med; 2010 Apr; 14(4):890-4. PubMed ID: 19818090
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Response by Endoplasmic Reticulum-Targeting DNA Vaccine Is Improved by Adding a KDEL Retention Signal.
Pérez-Trujillo JJ; Robles-Rodríguez OA; Garza-Morales R; García-García A; Rodríguez-Rocha H; Villanueva-Olivo A; Segoviano-Ramírez JC; Esparza-González SC; Saucedo-Cárdenas O; Montes-de-Oca-Luna R; Loera-Arias MJ
Nucleic Acid Ther; 2018 Aug; 28(4):252-261. PubMed ID: 29733248
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect.
Perez-Trujillo JJ; Garza-Morales R; Barron-Cantu JA; Figueroa-Parra G; Garcia-Garcia A; Rodriguez-Rocha H; Garcia-Juarez J; Muñoz-Maldonado GE; Saucedo-Cardenas O; Montes-De-Oca-Luna R; Loera-Arias MJ
Oncol Lett; 2017 Mar; 13(3):1569-1574. PubMed ID: 28454292
[TBL] [Abstract][Full Text] [Related]
4. Targeting HPV-16 antigens to the endoplasmic reticulum induces an endoplasmic reticulum stress response.
Martínez-Puente DH; Pérez-Trujillo JJ; Gutiérrez-Puente Y; Rodríguez-Rocha H; García-García A; Saucedo-Cárdenas O; Montes-de-Oca-Luna R; Loera-Arias MJ
Cell Stress Chaperones; 2019 Jan; 24(1):149-158. PubMed ID: 30604352
[TBL] [Abstract][Full Text] [Related]
5. Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
Lee SY; Oh JY; Kang TH; Shin HS; Cheng MA; Farmer E; Wu TC; Hung CF
J Biomed Sci; 2019 May; 26(1):41. PubMed ID: 31133013
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes.
Zhou F; Chen J; Zhao KN
J Gen Virol; 2013 Nov; 94(Pt 11):2504-2514. PubMed ID: 23956301
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of adenoviruses expressing mutant non-oncogenic E7 versions from HPV-16 fused to calreticulin.
Abigail Robles-Rodríguez O; Pérez Trujillo JJ; Barrón Cantú JA; Torres Cerda A; Gutiérrez Puente Y; García García A; Rodríguez Rocha H; Villanueva Olivo A; M Zavala Flores L; Saucedo Cárdenas O; Montes de Oca Luna R; de Jesús Loera Arias M
J BUON; 2020; 25(1):543-548. PubMed ID: 32277681
[TBL] [Abstract][Full Text] [Related]
9. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
10. Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes.
Hermiston TW; Tripp RA; Sparer T; Gooding LR; Wold WS
J Virol; 1993 Sep; 67(9):5289-98. PubMed ID: 8350398
[TBL] [Abstract][Full Text] [Related]
11. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
[TBL] [Abstract][Full Text] [Related]
12. Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect.
Martínez-Puente DH; Garza-Morales R; Pérez-Trujillo JJ; García-García A; Villanueva-Olivo A; Rodríguez-Rocha H; Zavala-Flores LM; Saucedo-Cárdenas O; Montes de Oca-Luna R; Loera-Arias MJ
J Drug Target; 2021 Dec; 29(10):1102-1110. PubMed ID: 33926356
[TBL] [Abstract][Full Text] [Related]
13. Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol.
Afshar N; Black BE; Paschal BM
Mol Cell Biol; 2005 Oct; 25(20):8844-53. PubMed ID: 16199864
[TBL] [Abstract][Full Text] [Related]
14. Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity.
Cheng WF; Lee CN; Su YN; Chai CY; Chang MC; Polo JM; Hung CF; Wu TC; Hsieh CY; Chen CA
Cancer Gene Ther; 2006 Sep; 13(9):873-85. PubMed ID: 16645621
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer.
Wu CC; Wu FC; Hsu YT; Hsiao YC; Yang YC; Chang CA; Chang CL
Oncotarget; 2017 May; 8(20):33024-33036. PubMed ID: 28423693
[TBL] [Abstract][Full Text] [Related]
16. Cell-penetrating and endoplasmic reticulum-locating TAT-IL-24-KDEL fusion protein induces tumor apoptosis.
Zhang J; Sun A; Xu R; Tao X; Dong Y; Lv X; Wei D
J Cell Physiol; 2016 Jan; 231(1):84-93. PubMed ID: 26031207
[TBL] [Abstract][Full Text] [Related]
17. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
Kim MS; Sin JI
Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
19. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
